z-logo
open-access-imgOpen Access
Treatment with Piperacillin‐Tazobactam and False‐PositiveAspergillusGalactomannan Antigen Test Results for Patients with Hematological Malignancies
Author(s) -
Olivier Adam,
Anne Aupérin,
Fanny Wilquin,
Jean Bourhis,
Bertrand Gachot,
Élisabeth Chachaty
Publication year - 2004
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/383148
Subject(s) - galactomannan , piperacillin/tazobactam , medicine , piperacillin , tazobactam , false positive paradox , breath test , gastroenterology , aspergillosis , exact test , hematology , immunology , biology , genetics , machine learning , bacteria , computer science , pseudomonas aeruginosa , helicobacter pylori
We report the occurrence of a high rate of false-positive test results during the surveillance of hematology patients for galactomannan (GM) antigenemia. Among 218 patients surveyed from June 2002 through June 2003, 42 (19.3%) had > or =1 serum sample positive for GM (optical density index, >1.5). Of these patients, 38 had no additional evidence of invasive aspergillosis, and, therefore, their test results were considered to be false-positives. Case-control analysis showed that treatment with piperacillin-tazobactam was the only risk factor significantly associated with receiving false-positive test results. When tested for GM antigen, 3 of 4 piperacillin-tazobactam batches had positive results. Physicians should be aware of the possible interference of treatment with piperacillin-tazobactam when interpreting the results of the GM assay.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom